Vimarsana
Biggest News Aggregation in the World

Page 30 - Drug Controller General News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Drug Controller General. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Drug Controller General Today - Breaking & Trending Today

AstraZeneca Pharma's Cancer-Treating Drug Gets Regulator's Nod In India - Vimarsana News

AstraZeneca Pharma's Cancer-Treating Drug Gets Regulator's Nod In India

AstraZeneca Pharma India Ltd on Wednesday said it has received an approval from the Drug Controller General of India (DCGI) for the cancer drug trastuzumab deruxtecan for treatment of metastatic breast cancer.

Source: ndtv.com
AstraZeneca gets approval to import breast cancer treatment drug in India - Vimarsana News

AstraZeneca gets approval to import breast cancer treatment drug in India

The India approval is based on a global, head-to-head, randomised, open-label, registrational Phase III trial of DESTINY Breast 03.

AstraZeneca gets approval to import breast cancer treatment drug in India - Vimarsana News

AstraZeneca gets approval to import breast cancer treatment drug in India

AstraZeneca Pharma India Ltd., a science-led biopharmaceutical company, on Wednesday announced that it has received approval from the Drug Controller General of

AstraZeneca gets approval to import breast cancer treatment drug in India - Vimarsana News

AstraZeneca gets approval to import breast cancer treatment drug in India

AstraZeneca Pharma India Ltd., a science-led biopharmaceutical company, on Wednesday announced that it has received approval from the Drug Controller General of Indi

NTF discusses strategies for COVID-19 in view of new virus strain from UK - Vimarsana News

NTF discusses strategies for COVID-19 in view of new virus strain from UK

The variant strain has 14 non-synonymous (amino acid altering) mutations, 6 synonymous (non-amino-acid altering), and 3 deletions.